Different genetic mutations cause different problems with this particular protein -- so CFTR modulators generally don't work ...

The CFTR Protein Distribution Core offers high-quality, full-length recombinant cystic fibrosis transmembrane conductance regulator (CFTR) proteins expressed in and purified from mammalian cells. Wild ...

Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.

The first CF rat model, CFTR tm1sage (termed CFTR-/- or KO), was designed in collaboration with SAGE (now Horizon Discovery) and subsequently characterized at UAB and distributed to the CF community.

See below for Important Safety Information, including a Boxed Warning. "ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to ...

The US Food and Drug Administration has approved Alyftrek, a once-daily oral combination of vanzacaftor, tezacaftor, and ...

Alyftrek is approved as a new treatment for cystic fibrosis, while the FDA expanded the label for Trikafta to include additional genetic mutations.

Alyftrek is a combination of three drugs — vanzacaftor (a CFTR potentiator), deutivacaftor (a CFTR corrector) and tezacaftor. We expect sales of this drug to drive growth in the medium term.

CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. An estimated 105,000 people have been diagnosed with CF across 94 countries, according to the CF ...

ALYFTREK™ is approved for patients 6 years and older with at least one responsive mutation, including 31 additional mutations not responsive to other CFTR modulator therapies - - In head-to-head ...

Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis ...